acks III EASTON BIOPHARMACEUTICALS 19 "提质增效重回报"行动方案 2024年度 股票代码 | 688513 EASTON BIOPHARMACEUTICALS 为践行"以投资者为本"的上市公司发展理念，推动上市公司持续优化经营、规范治 理和积极回报投资者，大力提高上市公司质量，成都苑东生物制药股份有限公司（ 以下简称"苑东生物"或"公司"）基于对未来发展前景的信心及价值的认可，特此制 定苑东生物2024年度"提质增效重回报"行动方案。 2024年，公司将积极采取措施，开展"提质增效重回报"专项行动，加大技术创新 的投入，加强内控管理，提高公司经营质量，以进一步巩固公司行业领先地位、提 升核心竞争力。同时，公司将强化管理层与股东利益共担共享，增强投资者回报和 获得感，保障投资者权益，树立良好的资本市场品牌形象。 the start of the ANT (1995) 1172 lid. Prop 2 - 2 - 2 持续保持高研发投入 锻造创新驱动发展引擎 苑东生物始终坚持"以患者为中心，为人类健康沐浴阳光"的企业使命，秉承" 阳光、价值、创新、高效"的价值观，以"成就自我 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥314,990,089.28, representing a year-on-year increase of 13.37%[3] - The net profit attributable to shareholders for the same period was ¥75,010,084.96, reflecting a growth of 23.00% compared to the previous year[3] - Operating profit for Q1 2024 was ¥80,220,974.65, up 17.5% from ¥68,278,212.94 in Q1 2023[19] - Net profit for Q1 2024 was ¥75,010,084.96, representing a 22.1% increase from ¥60,985,871.41 in Q1 2023[19] - Earnings per share for Q1 2024 were ¥0.63, compared to ¥0.51 in Q1 2023, reflecting a growth of 23.5%[20] - The total operating costs for Q1 2024 were ¥258,240,843.28, an increase of 14.0% from ¥226,451,481.30 in Q1 2023[18] Cash Flow - The net cash flow from operating activities increased significantly by 118.29%, amounting to ¥71,892,080.50[3][8] - Cash flow from operating activities for Q1 2024 was ¥71,892,080.50, significantly higher than ¥32,933,694.58 in Q1 2023[22] - The net cash flow from financing activities was -$63,998,569.10, indicating a significant outflow compared to the previous period's inflow of $49,320,319.44[23] - Total cash and cash equivalents at the end of the period amounted to $816,632,829.91, an increase from $767,540,657.11 at the beginning of the period[23] - Cash outflows from financing activities totaled $113,998,569.10, which included $60,000,000.00 for debt repayment and $1,281,279.84 for dividend payments[23] - The impact of exchange rate fluctuations on cash and cash equivalents was a decrease of $97,939.72[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,374,370,944.83, showing a slight increase of 0.83% from the end of the previous year[4] - As of March 31, 2024, total assets amounted to RMB 3,374,370,944.83, an increase from RMB 3,346,754,293.88 as of December 31, 2023, reflecting a growth of approximately 0.82%[16] - Total current liabilities were RMB 666,671,871.78, slightly up from RMB 661,094,015.47, showing an increase of approximately 0.87%[16] - The total liabilities amounted to RMB 748,260,937.50, up from RMB 743,334,130.15, indicating an increase of about 0.81%[16] - Non-current assets totaled RMB 1,470,683,597.65, a slight increase from RMB 1,463,883,064.24, reflecting a growth of approximately 0.14%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 3,619[10] - The company has not reported any significant changes in shareholder relationships or actions during the reporting period[12] Research and Development - Research and development expenses totaled ¥63,140,560.59, which is 20.05% of the operating revenue, an increase of 1.57 percentage points year-on-year[4] - Research and development expenses for Q1 2024 totaled ¥54,184,914.96, an increase from ¥50,088,561.76 in Q1 2023[19] Other Information - The company reported non-recurring gains of ¥22,918,205.83 for the quarter[7] - The weighted average return on equity was 2.87%, an increase of 0.41 percentage points compared to the previous year[3] - The total equity attributable to shareholders was ¥2,626,110,007.33, up by 0.87% from the previous year-end[4] - The company reported a total equity attributable to shareholders of ¥2,626,110,007.33, up from ¥2,603,420,163.73 in Q1 2023[17] - There were no new strategies or product developments mentioned in the conference call[13] - The company did not apply new accounting standards or interpretations for the first quarter of 2024[23]

成都苑东生物制药股份有限公司 董事会审计委员会对会计师事务所 履行监督职责情况报告 成都苑东生物制药股份有限公司（以下简称公司）聘请中汇会计师事务所（特 殊普通合伙）（以下简称"中汇会计师事务所"）作为公司 2023 年度年报审计师。 根据财政部、国资委及证监会颁布的《国有企业、上市公司选聘会计师事务 所管理办法》等规定和要求，公司董事会审计委员会本着勤勉尽责的原则，恪尽 职守，认真履职。现将董事会审计委员会对会计师事务所履行监督职责的情况汇 报如下： 一、2023 年年审会计师事务所基本情况 （一）会计师事务所基本情况 中汇会计师事务所，于 2013 年 12 月转制为特殊普通合伙，管理总部设立于 杭州，系原具有证券、期货业务审计资格的会计师事务所之一，长期从事证券服 务业务。 事务所名称：中汇会计师事务所（特殊普通合伙） 成立日期：2013 年 12 月 19 日 组织形式：特殊普通合伙 注册地址：杭州市江干区新业路 8 号华联时代大厦 A 幢 601 室 首席合伙人：余强 上年度末（2023 年 12 月 31 日）合伙人数量：103 人 上年度末（2023 年 12 月 31 日）注册会计师人数：70 ...

成都苑东生物制药股份有限公司 2023年度独立董事述职报告（彭龙） 履职情况报告如下： 在董事会和各专门委员会召开前，对会议相关审议事项进行较为全面的调查和了解，并 在必要时向公司进行问询，公司能够积极配合并及时进行回复。在会议召开过程中，就 审议事项与其他董事进行充分讨论，凭借自身积累的会计专业知识和执业经验向公司提 出合理化建议，并根据独立董事及各专门委员会的职责范围发表相关书面意见，积极促 进董事会决策的客观性、科学性，切实维护了公司和全体股东的利益。 作为成都苑东生物制药股份有限公司（以下简称"公司"）独立董事，本人在任职期内 严格依照《公司法》、《上海证券交易所科创板股票上市规则》、《上市公司治理准则》、 《上市公司独立董事管理办法》等法律法规及《公司章程》、《公司独立董事工作制度》等有 关规定和要求，忠实、勤勉、尽责的履行独立董事职责，切实维护公司以及全体股东尤其是 中小股东的合法权益。现将本人在2023年度任职期间（2023年5月6日-2023年12月31日） 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 因公司原独立董事尚姝女士任期已满6年，公司已于2023年4月12日和2 ...

Financial Performance - The company's operating revenue for 2023 was CNY 1,117,120,749.58, a decrease of 4.56% compared to CNY 1,170,512,900.63 in 2022 [22]. - The net profit attributable to shareholders for 2023 was CNY 226,574,420.57, down 8.09% from CNY 246,520,758.07 in 2022 [22]. - The net cash flow from operating activities increased by 81.15% to CNY 275,252,239.23 in 2023, compared to CNY 151,944,665.50 in 2022 [23]. - The total assets at the end of 2023 were CNY 3,346,754,293.88, reflecting a 10.91% increase from CNY 3,017,540,233.11 at the end of 2022 [23]. - The company's net assets attributable to shareholders increased by 6.50% to CNY 2,603,420,163.73 at the end of 2023, compared to CNY 2,444,459,716.15 at the end of 2022 [23]. - The basic earnings per share for 2023 were CNY 1.89, a decrease of 7.80% from CNY 2.05 in 2022 [24]. - The company's operating revenue for the reporting period was CNY 1,117.12 million, a decrease of 4.56% compared to CNY 1,170.51 million in the same period last year [135]. - The net profit attributable to shareholders was CNY 226.57 million, down 8.09% year-on-year; net profit excluding non-recurring gains and losses was CNY 157.58 million, a decrease of 4.32% [37]. Research and Development - Research and development expenses accounted for 22.03% of operating revenue in 2023, down from 22.65% in 2022 [24]. - The company has over 10 Class 1 innovative drugs in development, with EP-0108 capsules having received CDE clinical trial approval and EP-0146 tablets' clinical application accepted by CDE [59]. - The company is focusing on a research and development model driven by clinical needs, emphasizing small molecule innovative drugs, biological drugs, and high-end generic drugs [63]. - The company has a specialized R&D team of 442 personnel, including 178 with doctoral degrees, supporting continuous innovation and development [120]. - The company reported a total R&D expenditure of ¥246,087,516.90 in 2023, a decrease of 7.19% compared to ¥265,138,502.04 in the previous year [87]. - The company has applied for 63 new invention patents in 2023, bringing the total number of invention patents to 371, with 107 granted [85]. - The company is currently conducting Phase III clinical trials for one new chemical drug and has initiated Phase Ib/II trials for another biological drug [186]. Product Development and Approvals - The company has received approval for 10 formulation products, including critical drugs, and has a total of 48 high-end formulation products approved for market [42]. - The first internationalized formulation product, Nalmefene Hydrochloride Injection, received FDA approval [42]. - The company has submitted registration for multiple products, including Indobufen tablets with a production value of 1,462.08 million and a market value of 1,189.44 million [100]. - The company is developing a new injectable formulation of Bumetanide, which has a production value of 700.00 million and a market value of 629.82 million, leveraging its experience in injectable products [100]. - The company has submitted applications for several new products, including Nicardipine Hydrochloride Injection and Alprostadil Sodium Tablets, both classified as Class 4 [189]. - The company received approval for the production of multiple products in 2023, including Aripiprazole Oral Solution and Lacosamide Oral Solution, expanding its portfolio in psychiatric and epilepsy treatments [192]. - The company is actively pursuing regulatory approvals for its new products, which are expected to contribute to revenue growth in the coming years [192]. Market and Competitive Position - The company has a strong market presence, with three of its products ranking first in market share, including sodium namifen injection, naloxone injection, and ibuprofen injection [74]. - The company is expanding its international market presence, recently entering Poland and Kazakhstan as part of the Belt and Road Initiative [50]. - The company is focusing on high-quality development in the pharmaceutical industry, with key areas including oncology, cardiovascular diseases, and diabetes [166]. - The company aims to enhance operational efficiency and maintain competitiveness through integrated raw material and formulation strategies amid ongoing centralized procurement policies [169]. - The company is actively pursuing market expansion and product registration to enhance its competitive position in the pharmaceutical industry [104]. Risks and Challenges - The company has detailed various risks and countermeasures in its annual report, which investors should pay attention to [4]. - The company faces risks from national volume-based procurement policies, which could lead to price reductions for its products [123]. - The company received government subsidies amounting to 50.95 million RMB, accounting for 21.09% of total profit, indicating potential future risks if subsidy policies change [132]. - The ongoing reforms in the healthcare system and the promotion of consistent evaluations for generic drugs are enhancing the supply level of generic drugs in China [78]. Corporate Governance and Compliance - The company has confirmed that there are no non-operational fund occupations by controlling shareholders or related parties [9]. - The company has received a standard unqualified audit report from Zhonghui Certified Public Accountants [5]. - The company has not disclosed any special arrangements for corporate governance [9]. - The company has implemented a quality management system that has received multiple certifications, including ISO50001 and ISO14001 [47].

内部控制审计报告 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building. No. 8 Xinye Road. Qianjiang New City, Hangzhou Tel. 0571-88879999 Fax. 0571-88879000 www.zhcpa.cn "证明该审计报告是否由具有执业许可的会计师事务所出具， 十师行业统一监管平台（http://acc.mof.gov.cn）" 进行查验 （ 您可使用手机"扫一扫"或进入"注册会 十川市行业 成都苑东生物制药股份有限公司 成都苑东生物制药股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我 们审计了成都苑东生物制药股份有限公司(以下简称苑东生物公司)2023年12月31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部 控制评价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是苑东 生物公司董事会的责任。 二 ...

证券代码：688513 股票简称：苑东生物 公告编号：2024-020 成都苑东生物制药股份有限公司 关于 2024 年度公司与子公司申请综合授信额度并提 供相互担保的公告 一、2024 年度申请综合授信额度并提供担保情况概述 （一）基本情况 2024 年度公司及全资子公司拟向银行等金融机构申请不超过人民币 8.5 亿 元的综合授信额度，授信额度在有效期内可循环使用。授信业务包括但不限于贷 款、承兑汇票、贸易融资、保函等。授信具体业务品种、额度和期限，以金融机 构最终核定为准。以上授信额度不等于公司的实际融资金额，实际融资金额在总 授信额度内，以公司及全资子公司与金融机构实际发生的融资金额为准，具体融 资金额及品种将视公司业务发展的实际需求来合理确定。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为保证上述综合授信融资方案的顺利实施，根据公司及下属子公司的经营和 发展需要，在确保规范运作和风险可控的前提下，公司拟为下属全资子公司（含 1 ● 本次担保无反担保。 ● 本议案无需提交股东大会审议。 重要内容提示： ● 担保 ...

证券代码：688513 证券简称：苑东生物 公告编号：2024-018 成都苑东生物制药股份有限公司 第三届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 监事会会议召开情况 成都苑东生物制药股份有限公司（以下简称"公司"）第三届监事会第十三次 会议于 2024 年 4 月 22 日在公司会议室以现场形式召开。会议通知已于 2024 年 4 月 12 日以书面方式、电话通知等方式送达全体监事。本次会议应出席监事 3 名，实际出席监事 3 名，本次会议由监事会主席朱家裕先生主持，公司董事会秘 书等列席会议。本次会议的召集和召开程序符合有关法律、行政法规、部门规章、 规范性文件和《公司章程》的规定，会议决议合法、有效。 二、 监事会会议审议情况 经审议，会议以投票表决的方式通过以下议案： （一）审议通过《关于<公司 2023 年度监事会工作报告>的议案》 监事会认为：报告期内，监事会严格按照《公司法》等有关法律法规和《公 司章程》、公司《监事会议事规则》的要求，遵守诚信原则，从切实维护公司利 ...

成都苑东生物制药股份有限公司 年度募集资金存放与使用情况鉴证报告 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 www.zhcpa.cn 目 景 | | 页 次 | | --- | --- | | 一、年度募集资金存放与使用情况鉴证报告 | 1-3 | | 二、成都苑东生物制药股份有限公司关于 2023年度募集资金 | | | 存放与使用情况的专项报告 | 4-14 | 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New City, Hangzhou www.zhcpa.cn Tel. 0571-88879999 年度募集资金存放与使用情况鉴证报告 中汇会鉴[2024 ...

经全体与会独立董事审议：本次关联交易是基于公司及合并报表范围内子公 司正常生产、经营活动所必要的，是公司合理利用资源的重要手段。各项日常关 联交易的定价政策严格遵循公开、公平、公正、等价有偿的一般商业原则，有利 于公司相关业务的开展，不会对公司持续经营能力、盈利能力及资产独立性等产 生不利影响，不存在对关联人形成较大依赖的情形，符合有关法律法规及《公司 章程》的规定，不存在损害公司和公司股东利益，特别是中小股东的利益的情形。 我们同意将该关联交易事项提交公司第三届董事会第十七次会议审议，届时关联 董事将回避表决。 一、审议通过《关于推举第三届独立董事专门会议召集人的议案》 成都苑东生物制药股份有限公司 经过半数以上独立董事推举，公司第三届独立董事专门会议召集人由独立董 事彭龙先生召集并主持，任期与第三届董事会任期相同。 第三届独立董事专门会议第一次会议决议 表决结果：3 票同意、0 票反对、0 票弃权。 成都苑东生物制药股份有限公司（以下称"公司"）第三届独立董事专门会议 第一次会议通知于 2024 年 4 月 8 日以电话等方式向全体独立董事发出，会议于 2024 年 4 月 12 日以通讯表决方式召开。本 ...